Senores Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 15.1%)
- Low debt relative to equity (D/E 0.4x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SENORES · as of Jun 2026
| Category | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 45.78% | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% |
| FII | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% |
| DII | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% |
| Public | 40.39% | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
Latest News
All newsSenores Pharma to host analyst and investor meet
*Senores Pharma to host analyst and investor meet.* The company has announced a schedule for its upcoming investor interaction. Details on business outlook and performance may be discussed. No financial figures or major announcements disclosed yet. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Senores Pharma publishes annual report dispatch notice
*Senores Pharma publishes annual report dispatch notice.* The company has released a newspaper publication confirming the pre-dispatch of its **Annual Report** for the upcoming Annual General Meeting. This is a routine compliance requirement under corporate filing norms. No financial or operational updates were disclosed. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport
Senores Pharma to host analyst call for Q1FY27.
*Senores Pharma to host analyst call for Q1FY27.* The company will conduct an investor meet on **July 27, 2026**, to discuss quarterly performance. This event offers clarity on recent financials and management outlook. Investors may anticipate guidance or strategic updates. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Senores Pharmaceuticals publishes newspaper notice
Senores Pharmaceuticals Limited released a copy of its newspaper publication as part of regulatory compliance. The filing contains no financial or operational updates. Such disclosures are routine and typically informational in nature. No immediate market-moving developments were indicated. 📊 *STOCKS:* SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Senores Pharma to host analyst and investor meet
*Senores Pharma to host analyst and investor meet.* The company has announced a schedule for its investor interaction. No financial updates or guidance changes were disclosed. Event aimed at enhancing institutional engagement. 📊 *STOCKS:* SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹175 Cr 2.3% | ₹171 Cr 5.6% | ₹162 Cr 17.4% | ₹138 Cr 21.1% | ₹114 Cr 10.7% | ₹103 Cr 2.0% | ₹101 Cr 26.3% | ₹80 Cr |
| Op. Profit | ₹47 Cr 6.0% | ₹50 Cr 0.0% | ₹50 Cr 47.1% | ₹34 Cr 78.9% | ₹19 Cr 26.9% | ₹26 Cr 13.0% | ₹23 Cr 9.5% | ₹21 Cr |
| OPM | 27.0% 6.9% | 29.0% 6.5% | 31.0% 24.0% | 25.0% 47.1% | 17.0% 32.0% | 25.0% 8.7% | 23.0% 14.8% | 27.0% |
| Net Profit | ₹37 Cr 8.8% | ₹34 Cr 13.3% | ₹30 Cr 42.9% | ₹21 Cr 16.7% | ₹18 Cr 12.5% | ₹16 Cr 23.1% | ₹13 Cr 18.2% | ₹11 Cr |
| EPS (₹) | 6.86 0.1% | 6.87 2.3% | 7.03 64.3% | 4.28 10.6% | 3.87 3.8% | 3.73 3.4% | 3.86 19.5% | 3.23 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | ₹633 Cr 59.0% | ₹398 Cr 85.1% | ₹215 Cr 514.3% | ₹35 Cr 150.0% | ₹14 Cr |
| Expenses | ₹464 Cr 50.2% | ₹309 Cr 78.6% | ₹173 Cr 652.2% | ₹23 Cr 91.7% | ₹12 Cr |
| Op. Profit | ₹168 Cr 86.7% | ₹90 Cr 114.3% | ₹42 Cr 223.1% | ₹13 Cr 550.0% | ₹2 Cr |
| OPM | 27.0% 17.4% | 23.0% 21.1% | 19.0% 47.2% | 36.0% 157.1% | 14.0% |
| Other Income | ₹47 Cr 147.4% | ₹19 Cr 533.3% | ₹3 Cr 25.0% | ₹4 Cr | ₹0 Cr |
| Interest | ₹25 Cr 13.6% | ₹22 Cr 144.4% | ₹9 Cr 350.0% | ₹2 Cr 100.0% | ₹1 Cr |
| Depreciation | ₹31 Cr 82.4% | ₹17 Cr 70.0% | ₹10 Cr 400.0% | ₹2 Cr 100.0% | ₹1 Cr |
| PBT | ₹159 Cr 123.9% | ₹71 Cr 184.0% | ₹25 Cr 108.3% | ₹12 Cr 1100.0% | ₹1 Cr |
| Tax % | 24.0% 41.2% | 17.0% 154.8% | -31.0% 196.9% | 32.0% 146.2% | 13.0% |
| Net Profit | ₹122 Cr 110.3% | ₹58 Cr 75.8% | ₹33 Cr 312.5% | ₹8 Cr 700.0% | ₹1 Cr |
| EPS (₹) | 25.05 96.9% | 12.72 23.4% | 10.31 20.0% | 8.59 750.5% | 1.01 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Liabilities | |||||
| Equity Capital | ₹46 Cr 0.0% | ₹46 Cr 48.4% | ₹31 Cr 210.0% | ₹10 Cr 11.1% | ₹9 Cr |
| Reserves | ₹888 Cr 20.0% | ₹740 Cr 325.3% | ₹174 Cr 383.3% | ₹36 Cr 28.6% | ₹28 Cr |
| Borrowings | ₹342 Cr 8.6% | ₹315 Cr 22.1% | ₹258 Cr 309.5% | ₹63 Cr 320.0% | ₹15 Cr |
| Other Liabilities | ₹328 Cr 160.3% | ₹126 Cr 21.3% | ₹160 Cr 595.7% | ₹23 Cr 187.5% | ₹8 Cr |
| Total Liabilities | ₹1.6K Cr 30.7% | ₹1.2K Cr 97.3% | ₹622 Cr 374.8% | ₹131 Cr 122.0% | ₹59 Cr |
Assets | |||||
| Fixed Assets | ₹755 Cr 150.8% | ₹301 Cr 28.1% | ₹235 Cr 770.4% | ₹27 Cr 285.7% | ₹7 Cr |
| CWIP | ₹17 Cr 90.1% | ₹172 Cr 77.3% | ₹97 Cr 185.3% | ₹34 Cr 325.0% | ₹8 Cr |
| Investments | ₹4 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹16 Cr 6.7% | ₹15 Cr |
| Other Assets | ₹827 Cr 9.7% | ₹754 Cr 160.9% | ₹289 Cr 445.3% | ₹53 Cr 82.8% | ₹29 Cr |
| Total Assets | ₹1.6K Cr 30.7% | ₹1.2K Cr 97.3% | ₹622 Cr 374.8% | ₹131 Cr 122.0% | ₹59 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating CF | ₹62 Cr 234.8% | ₹-46 Cr 76.9% | ₹-26 Cr 2500.0% | ₹-1 Cr 90.0% | ₹-10 Cr |
| Investing CF | ₹-121 Cr 71.8% | ₹-429 Cr 694.4% | ₹-54 Cr 12.5% | ₹-48 Cr 100.0% | ₹-24 Cr |
| Financing CF | ₹-1 Cr 100.2% | ₹573 Cr 558.6% | ₹87 Cr 89.1% | ₹46 Cr 27.8% | ₹36 Cr |
| Net Cash Flow | ₹-60 Cr 161.2% | ₹98 Cr 1125.0% | ₹8 Cr 366.7% | ₹-3 Cr 250.0% | ₹2 Cr |
| Free Cash Flow | ₹-203 Cr 0.0% | ₹-203 Cr 160.3% | ₹-78 Cr 62.5% | ₹-48 Cr 128.6% | ₹-21 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Debtor Days | 187d 64.0% | 114d 40.3% | 191d 16.2% | 228d 54.9% | 506d |
| Inventory Days | 130d 44.0% | 232d 26.1% | 184d 106.7% | 89d 34.1% | 135d |
| Days Payable | 340d 23.6% | 275d 50.5% | 556d 43.3% | 388d 19.8% | 324d |
| Cash Conv. Cycle | -24d 134.3% | 70d 138.5% | -182d 156.3% | -71d 122.4% | 317d |
| Working Capital Days | 132d 50.0% | 88d 650.0% | -16d 128.6% | -7d 101.9% | 359d |
| ROCE | 15.0% 36.4% | 11.0% 8.3% | 12.0% 33.3% | 18.0% | — |
Source: Screener.in · Lower days = better efficiency